Search Result

Results for "

ME+1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (8) Autophagy (2) Bcl-2 Family (1) Beclin1 (1) Caspase (1) CD44 (1) Epigenetic Reader Domain (1) Fatty Acid Synthase (FASN) (1) Histone Demethylase (9) Histone Methyltransferase (7) Interleukin Related (1) LDLR (1) Microtubule/Tubulin (2) Mitochondrial Metabolism (1) PD-1/PD-L1 (1) Small Interfering RNA (siRNA) (5) Thyroid Hormone Receptor (1) TLK (1) Topoisomerase (1) Wee1 (1) Wnt (1) Zinc Finger Protein (1) β-catenin (1)
By Research Areas:	Cancer (23) Infection (2) Inflammation/Immunology (3) Metabolic Disease (2)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (2) siRNAs (5)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Oligonucleotides

Targets Recommended: Measles Virus

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15227

EPZ004777 Maximum Cited Publications 10 Publications Verification	Histone Methyltransferase Apoptosis	Inflammation/Immunology Cancer
EPZ004777 is an effective and selective *DOT1L* inhibitor, with IC₅₀ being 0.4 nM. EPZ004777 reduces the levels of H3K79me2 and *H3K79me1, significantly down-regulating the expression of HOXA9* and *MEIS1. EPZ004777 selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis*) of leukemia cells. EPZ004777 can be used for the study of leukemia ^[1] .

HY-124861

Malic enzyme inhibitor ME1 5 Publications Verification ME1	Fatty Acid Synthase (FASN)	Metabolic Disease Cancer
Malic enzyme inhibitor ME1 (ME1; compound 1) is a potent inhibitor of Malic enzyme (ME1) with an IC₅₀ of 0.15 μM ^[1] .

HY-150621

AS1134900	β-catenin Wnt	Cancer
AS1134900 is a highly selective uncompetitive allosteric inhibitor of NADP ⁺-dependent malic enzyme 1 (ME1) with an IC₅₀ of 0.73 μM. AS1134900 can be used in the study of cancer ^[1].

HY-403538

iZMYND8-34	Zinc Finger Protein	Cancer
iZMYND8-34 is a ZMYND8 inhibitor with an IC₅₀ of 0.66 μM. iZMYND8-34 inhibits the binding of H3K4me1–H3K14ac peptide to the ZMYND8 protein. iZMYND8-34 inhibits ZMYND8’s histone recognition. iZMYND8-34 blocks neuroendocrine prostate cancer development ^[1].

HY-P99595

Sirtratumab vedotin AGS15E; ASG-15ME; 1vcMMAE	Antibody-Drug Conjugates (ADCs)	Cancer
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker ^[1].

HY-15227A

EPZ004777 hydrochloride Maximum Cited Publications 10 Publications Verification	Histone Methyltransferase Apoptosis	Inflammation/Immunology Cancer
EPZ004777 hydrochloride is an effective and selective *DOT1L* inhibitor, with IC₅₀ being 0.4 nM. EPZ004777 hydrochloride reduces the levels of H3K79me2 and *H3K79me1, significantly down-regulating the expression of HOXA9* and *MEIS1. EPZ004777 hydrochloride selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis*) of leukemia cells. EPZ004777 hydrochloride can be used for the study of leukemia ^[1] .

HY-149091

KDM5B-IN-4	Histone Demethylase	Cancer
KDM5B-IN-4 (compound 11ad) is a lysine demethylase 5B (KDM5B) inhibitor with an IC₅₀ of 0.025 μM KDM5B-IN-4 increases substrate H3K4me1/2/3 level by inhibiting KDM5B in PC-3 cells. KDM5B-IN-4 downregulates PI3K/AKT. KDM5B-IN-4 reduces tumor volume in mice and shows less toxic to organs ^[1].

HY-128912

Arborinine	Histone Demethylase	Cancer
Arborinine is a potent and orally activeLSD1 inhibitor. Arborinine increases the expression of H3K4me1/2, H3K9me1/2, E-cad protein and decreases the expression of UBE2O protein level. Arborinine induces cell cycle arrest at S phase. Arborinine shows antitumor activity ^[1] .

HY-P991080

Anti-SLC44A4 Antibody ASG-5ME Antibody; AGS-5M2	ADC Antibody	Cancer
Anti-SLC44A4 Antibody (ASG-5ME Antibody) is a SLC44A4 targeting antibody that can be used for synthesis of ADC ASG-5ME .

HY-P2254

H3K27(Me3) (15-34)	Histone Methyltransferase	Cancer
H3K27(Me3) (15-34), a histone peptide, is a repressive chromatin mark derived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

HY-149677

ZK53	Mitochondrial Metabolism	Cancer
ZK53 is a selective activator of mitochondrial caseinolytic protease P (HsClpP) (EC₅₀: 1.37?μM for α-casein hydrolysis by HsClpP). ZK53 is is inactive toward bacterial ClpP proteins. ZK53 induces apoptosis in H1703, H520 and SK-MES-1 cells. ZK53 induces dysregulation of mitochondrial functions in lung squamous cell carcinoma (LUSC) cells. ZK53 inhibits tumor growth in H1703 xenograft mouse model ^[1].

HY-172661

Kylo-0603	Thyroid Hormone Receptor Interleukin Related LDLR	Infection Metabolic Disease
KYLO-0603 is an orally active, selective THR-β agonist (EC₅₀ : 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research ^[1].

HY-P2255

*H3K4(Me) (1-20)*	Histone Demethylase	Others
H3K4(Me) (1-20), a histone peptide. H3K4me is an intricately regulated posttranslational modification, which is broadly associated with enhancers and promoters of actively transcribed genomic loci ^[1].

HY-RS08270

ME1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ME1 Human Pre-designed siRNA Set A contains three designed siRNAs for ME1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ME1 Human Pre-designed siRNA Set A ME1 Human Pre-designed siRNA Set A

HY-RS17185

Me1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Me1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Me1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Me1 Mouse Pre-designed siRNA Set A Me1 Mouse Pre-designed siRNA Set A

HY-RS23636

Me1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Me1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Me1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Me1 Rat Pre-designed siRNA Set A Me1 Rat Pre-designed siRNA Set A

HY-164144

EPZ033294	Histone Methyltransferase	Cancer
EPZ033294 is an inhibitor of SYMD2 (IC₅₀ is 3.9 nM). SYMD2 itself has catalytic activity and can methylate the lysine residue of BTF3 to BTF3me1, which was experimentally demonstrated by detecting an IC₅₀ of 2.9 nM for inhibition of BTF3ME1 by SYMD2, indicating an active inhibition of SYMD2 by EPZ033294. EPZ033294 (0-50 µM) has an inhibitory effect on SYMD2 and a concentration-dependent inhibitory effect in 293T ^[1].

HY-176283

Tubulin/LSD1-IN-1	Microtubule/Tubulin Histone Demethylase Apoptosis Wee1 Bcl-2 Family Caspase	Cancer
Tubulin/LSD1-IN-1 is an effective dual inhibitor of Tubulin polymerization and *LSD1* (IC₅₀ = 1.72 μM). Tubulin/LSD1-IN-1 has broad-spectrum antiproliferative activity against cancer cell lines. Tubulin/LSD1-IN-1 inhibits tubulin polymerization by targeting colchicine binding sites, thereby disrupting the microtubule network in gastric cancer cells. Tubulin/LSD1-IN-1 increases the methylation levels of H3K4me1/2 and H3K9me2/3, thereby achieving epigenetic regulation. Tubulin/LSD1-IN-1 induces G2/M arrest, promotes apoptosis, and effectively inhibits colony formation of gastric cancer cells ^[1].

HY-149213

LSD1/TLK1-IN-1 J54; J3-54	Histone Demethylase TLK	Cancer
LSD1/TLK1-IN-1 is an orally active *LSD1, TLK1, TLK2, TTK* inhibitor with an *LSD1* IC₅₀ of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1>Nek1>ATR>Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect LSD2, MAO-A, or MAO-B. LSD1/TLK1-IN-1 induces apoptosis, bypasses cell-cycle arrest, suppresses tumor growth, acts as a weak D4R antagonist, downregulates *PD-L1* expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation, shows minimal toxicity, and has no significant effect on normal prostate cells. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer ^[1] .

HY-RS10137

PCDHB16 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PCDHB16 Human Pre-designed siRNA Set A contains three designed siRNAs for PCDHB16 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PCDHB16 Human Pre-designed siRNA Set A PCDHB16 Human Pre-designed siRNA Set A

HY-182054

*Topoisomerase ll/ME-1-IN-1*	Topoisomerase Beclin1 Autophagy Apoptosis	Cancer
Topoisomerase ll/ME-1-IN-1 (Compound 7a) is a Topoisomerase ll and *ME-1* inhibitor with an IC₅₀ of 5.03 μM against Topoisomerase ll. Topoisomerase ll/ME-1-IN-1 functionally inhibits the activity of Topoisomerase II and functionally blocks the activity of ME-1. Topoisomerase ll/ME-1-IN-1 induces Autophagy by upregulating the expression of *Beclin-1* and LC3-II. Topoisomerase ll/ME-1-IN-1 promotes Apoptosis. Topoisomerase ll/ME-1-IN-1 exhibits antiproliferative activity against breast cancer cells and shows no toxicity to normal mammary epithelial cells. Topoisomerase ll/ME-1-IN-1 can be used in studies related to breast cancer (including triple-negative breast cancer) ^[1].

HY-P2252

H3K27(Me) (15-34)	Histone Methyltransferase	Cancer
H3K27(Me) (15-34), a histone peptide, is a repressive chromatin markderived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

HY-P2253

H3K27(Me2) (15-34)	Histone Demethylase	Cancer
H3K27(Me2) (15-34), a histone peptide, is a repressive chromatin mark derived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

HY-158436

Antitumor agent-155	Microtubule/Tubulin Autophagy Apoptosis	Cancer
Antitumor agent-155 (Compound 13) inhibits microtubule polymerization, induces autophagy and apoptosis. Antitumor agent-155 shows cytotoxicity against HCT116, A549, AGS, SK-MES-1 cells with IC₅₀s of 0.227, 0.253, 0.574, 0.423 μM respectively ^[1].

HY-174450

KMT9-IN-1	Epigenetic Reader Domain	Cancer
KMT9-IN-1 (Compound 8) is a KMT9 inhibitor and the ethyl ester prodrug of compound 7b. KMT9-IN-1 releases the active form 7b via esterases in cells. KMT9-IN-1 targets KMT9 in cells and reduces H4K12me1 levels. KMT9-IN-1 has antitumor activity against colon cancer. KMT9-IN-1 can be used in the research of prostate cancer and hepatocellular carcinoma ^[1].

HY-168086

LSD1-IN-35	PD-1/PD-L1 Histone Demethylase	Infection Inflammation/Immunology
LSD1-IN-35 (Compound Z-1) is a selective *LSD1* Inhibitor (IC₅₀: 108 nM). LSD1-IN-35 inhibits the demethylation on *H3K4me1/2. LSD1-IN-35* is an immunomodulator. LSD1-IN-35 promotes response of gastric cancer cells to T-cell killing effect by decreasing PD-L1 expression and further attenuates the PD-1/PD-L1 interaction ^[1].

HY-P10819

S9-CMC1 TFA	Histone Demethylase Apoptosis	Cancer
S9-CMC1 TFA is a covalent peptide lysine-specific demethylase 1 (LSD1) inhibitor with an IC₅₀ value of 2.53 μM. S9-CMC1 TFA specifically recognizes Cys360 in the enzyme-active region. S9-CMC1 TFA inhibits *LSD1* activity, increasing H3K4me1 and H3K4me2 levels, leading to G1 cell cycle arrest and apoptosis and inhibiting cell proliferation. S9-CMC1 TFA significantly inhibits tumor growth in A549 xenograft animal models ^[1].

HY-RS21063

Tcf12 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tcf12 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tcf12 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tcf12 Mouse Pre-designed siRNA Set A Tcf12 Mouse Pre-designed siRNA Set A

HY-115619

EPZ004777 formate	Histone Methyltransferase Apoptosis	Cancer
EPZ004777 formate is an effective and selective *DOT1L* inhibitor, with IC₅₀ being 0.4 nM. EPZ004777 formate reduces the levels of H3K79me2 and *H3K79me1, significantly down-regulating the expression of HOXA9* and *MEIS1. EPZ004777 formate selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis*) of leukemia cells. EPZ004777 formate can be used for the study of leukemia ^[1] .

HY-181849

MS2928	Histone Methyltransferase	Cancer
MS2928 is a selective SETD8 inhibitor with an IC₅₀ of 0.14 μM against SETD8 methyltransferase activity. MS2928 reduces cellular *H4K20_me1* levels and inhibits proliferation of SETD8-overexpressing multiple myeloma cells. MS2928 inhibits tumor growth in xenograft mouse models of SETD8-overexpressing multiple myeloma. MS2928 can be used for the study of SETD8 biological functions and multiple myeloma ^[1].

HY-181781

LSD1-IN-48	Histone Demethylase CD44 Apoptosis	Cancer
LSD1-IN-48 is a tranylcypromine-pyrimidine derivative and selective *LSD1* inhibitor with a human IC₅₀ of 7.87 nM. LSD1-IN-48 increases *H3K4me1/2* histone methylation levels. LSD1-IN-48 induces apoptosis, upregulates CD86, downregulates SOX2 and CD44, inhibits proliferation in cancer cells. LSD1-IN-48 can be used for the research of acute myeloid leukemia ^[1].

Cat. No.	Product Name	Target	Research Area